Top Research Studies on GLP-1s and Cardiovascular Outcomes The November 2023 issue of The New England Journal of Medicine shared results from a research study (SELECT) involving 17,000 patients that showed the use of semaglutide was linked to a 20% reduction in the risk of major adverse cardiovascular events such as heart disease, stroke and peripheral arterial disease in patients who had previously been diagnosed with heart disease
Unlike dental coverage or life insurance multiples, parental leave generates direct, personal financial calculations: how much will I receive, for how long, and what will that mean for my familys finances and my ability to be present during a period that does not repeat
Your provider may start with one peptide and add the second if needed
Wegovy is intended for long-term use, with the best weight loss results achieved by reaching the maximum 2.4mg dose and taking it consistently as prescribed
Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, works by slowing gastric emptying, which can lead to feelings of abdominal fullness and distension
Retatrutide is Eli Lilly's investigational triple-receptor agonist - one weekly injection that acts on GLP-1, GIP, and glucagon receptors at once to cut appetite, improve insulin signaling, and raise energy use
